IntoCell, Inc. Logo

IntoCell, Inc.

Develops and licenses proprietary ADC platform technologies for cancer & immune therapies.

287840 | KO

Overview

Corporate Details

ISIN(s):
KR7287840003
LEI:
Country:
South Korea
Address:
대전광역시 대덕구 신일동로 101, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IntoCell, Inc. is a biotechnology company specializing in the research and development of novel biopharmaceuticals. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) platform technologies, including its OHPAS™ linker and Payload Modification Technology. IntoCell leverages these platforms to develop targeted therapies for cancer and immunological disorders. The company's business model is centered on the commercialization and transfer of its innovative ADC technologies to global partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (ITC6146RO의 한국 MFDS 제1상 임상시험계획 승인신청)
Korean 8.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 758.7 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-07-09 00:00
Regulatory News Service
투자판단관련주요경영사항 (ADC 플랫폼 기술에 대한 실시권 계약 해지)
Korean 6.6 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.8 KB
2025-06-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.6 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 73.6 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 185.8 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.6 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all IntoCell, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IntoCell, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IntoCell, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.